Fairvalue-Calculator Fairvalue-Calculator
EN DE

Opus Genetics, Inc (IRD) Fair Value & Analysis

Healthcare · US · Market cap $336M

Price$4.08
Fair Value$0.8400
Upside-79.4%
Quality95/100
Evidence: Low Range $0.6300 – $1.05

Fair value as of: Jun 24, 2026

Analysis

Opus Genetics, Inc (IRD) currently trades at $4.08, while our model-based Fair Value estimate is $0.8400 — implying the stock looks roughly 79.4% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease cau…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Opus Genetics, Inc (IRD) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $0.8400 versus a price of $4.08 — about −79% (overvalued). Model-based estimate, not financial advice.
What is the fair value of IRD?
Our 21-model fair value for Opus Genetics, Inc is $0.8400 (as of Jun 24, 2026), built from audited fundamentals. The current price is $4.08.
What is the quality score of IRD?
Opus Genetics, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.